PD-1 Round-Up: Bristol's Lead Grows, But Field Could Soon See Major Change
Leading sponsors of PD-1/L1 checkpoint inhibitors looked back on a string of successes and ahead toward the future for combinations with a wide range of other targets during full-year earnings calls.
You may also be interested in...
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.
Patients with the most severe type of disease were all randomized to treatment with the study drug, which may have had a negative impact on outcome, the Israeli company suggested.